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A Consensus Document   
 
Introduction   
Pregnancy has been reported to be associated with an increased risk of ischemic stroke and stroke occurring 
during pregnancy is one of the leading causes of maternal death1. Kuklina et al. reported that the rate of any 
stroke among antenatal hospitalizations increased by 47% (from 0.15 to 0.22 per 1000 deliveries) and among 
postpartum hospitalizations by 83% (from 0.12 to 0.22 per 1000 deliveries) when comparing the period 
1994-1995 to 2006-20072.  
The AHA Stroke Guidelines for Women have been published recently3 which deal with risk factors unique 
to women, including reproductive factors, and those factors that are more common in women, including 
migraine, obesity, metabolic syndrome, and atrial fibrillation. However, the lifelong management of 
hormonal issues in women who have had stroke was not fully addressed regarding:  future pregnancies, type 
of delivery, labor induction and secondary prevention during future pregnancy and lactation.  
This consensus provides multidisciplinary approaches compiled by stroke neurologists, gynecologists and 
endocrinologists, based upon a thorough review of current literature through computerized searches up until 
July 26, 2016. 
 
Methods:  
Literature on pregnancy, secondary stroke prevention, labor induction, hormonal contraceptive therapy, 
ovarian stimulation and hormone replacement therapy, was reviewed. The panel collected relevant articles 
using computerized searches of medical literature up until July 26, 2016. The search strategy was designed 
to identify studies on pregnancy, delivery, labor induction, breastfeeding, ovarian stimulation, hormonal 
contraceptive therapy, hormonal replacement therapy and their stroke risks. The included studies were 
identified from the Medline/PubMed database, EMBASE, and the Cochrane Database. Additional papers 
were identified from reference lists of retrieved articles, abstract lists of recent scientific meetings, and 
Internet-based sources [(www.tctmd.com, www.cxvascular.com), see Figure 1.]   
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A list of treatment recommendations including evaluations of evidence strength is provided (Tab. 1).   
Recommendations were rated as Grades of Recommendation Assessment, Development and Evaluation 
(GRADE) 1 (strong: when benefit clearly outweighed risk and could be accepted with a high degree of 
confidence) or GRADE 2 (weak: when the benefits and risks were more closely matched and were more 
dependent on specific clinical scenarios) and divided into 3 level categories: A (high quality), B (moderate 
quality), and C (low quality). Statements for issues where there was limited evidence were rated as good 
clinical practice. 
A worldwide search was carried out to select the panel members who were considered to be both expert 
clinicians and researchers in the fields of stroke neurology, endocrinology or gynecology. Using the Delphi 
method, members of the panel were asked to evaluate their agreement on hormonal use, type of delivery and 
secondary prevention treatment during pregnancy in women with previous stroke.  
Recommendations were drafted when an agreement was reached among a majority of panelists. In the 
absence of a majority, current literature was reviewed and re-analyzed and a new version of the document, 
based upon suggestions furnished by the panelists, was drafted (Tab. 1).  
 
1. Future Pregnancies and Secondary Stroke Prevention Therapy with Antithrombotics  
The only data available on the risk of recurrent stroke in women of child-bearing age, comes from a 
multicenter study4 on 373 consecutive women who had already had an ischemic stroke between 25-40 years 
of age. An overall risk of recurrent stroke of 0.5% at year-5 (95% CI: 0.3-0.95) in non-pregnant periods 
compared to 1.8% (95% CI: 0.5-7.5) during pregnancy.  
Whereas, the risk of stroke was reported to be significantly higher during the postpartum period (risk ratio 
(RR) = 9.7; 95% CI 1.2, 78.9) than during pregnancy (RR = 2.2; 95% CI 0. 3, 17.5)4. The risks of ischemic 
and hemorrhagic stroke have been  reported to be greater in the first six weeks after delivery; with an overall 
risk estimated to be 8.1 strokes per 100,000 pregnancies (95% CI, 6.4, 9.7) 5. The risk of thrombotic events 
in the postpartum period has been reported to be markedly higher within 6-weeks after delivery (OR = 10.8; 
95% CI 7.8, 15.1)6.  
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For stroke prevention treatment during pregnancy, recommendations are based on 2 scenarios: a high-risk 
condition that would have  called  for anticoagulation, or a lower-risk condition that would have  called for 
antiplatelet therapy outside pregnancy (Tab. 1). 
Anticoagulants 
Neither unfractionated heparin (UFH) nor low molecular weight heparin (LMWH) cross the placenta and 
therefore do not have the potential to cause fetal bleeding or teratogenicity; although bleeding at the utero-
placental junction has been reported7. 
The use of UFH has been associated with maternal risks including thrombocytopenia (HIT) and osteoporosis. 
Furthermore, the administration of therapeutic doses of UFH requires regular laboratory monitoring of the 
activated partial thromboplastin time (APTT).  
Whereas, LMWH offers a number of advantages over UFH, due to its better bioavailability, longer plasma 
half-life, more predictable dose response, and improved safety profiles especially for osteoporosis and HIT7. 
Unlike heparin, coumarin derivatives (such as warfarin) can cross the placenta and therefore can lead to 
bleedings in the fetus and teratogenicity.7 These have been reported to occur when oral anticoagulants are 
administered between the 6th and 12th weeks of gestation, whereas oral anticoagulants are less likely to be 
fetopathic when administered in the first 6 weeks of gestation.8 Finally, warfarin  has been reported to lead 
to fetal bleeding during delivery.9 
A systematic review9 in patients with mechanical heart valve (MHV) reported that the use of OA throughout 
pregnancy was associated with warfarin embryopathy in 6.4% (95% CI, 4.6%-8.9%) of live births. The 
substitution of heparin at or prior to 6 weeks, and continued until the 12 week, eliminated this risk. Overall 
risks for fetal wastage were similar in women treated with OA throughout pregnancy, compared to those 
treated with heparin in the first trimester. Maternal mortality occurred in 2.9% (95% CI, 1.9%-4.2%). Major 
bleeding events were recorded at 2.5% (95% CI, 1.7%-3.5%) of all pregnancies, with most occurring at the 
time of delivery. The use of OA throughout pregnancy was associated with the lowest risk of valve 
thrombosis (3.9%; 95% CI, 2.9-5.9%); whereas heparin use between weeks 6 and 12 was associated with 
the highest risk of valve thrombosis (9.2%; 95% CI, 5.9%-13.9%) (Tab 2).9 Moreover, data collected from 
the Registry of Pregnancy and Cardiac disease (ROPAC) comparing  patients with MHV to those with tissue 
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heart valves (THV) and those without  prosthetic valves (PV), reported a  maternal mortality rate  of 1.4% 
in MHV, 1.5%  for  those with THV (P=1.000), and 0.2% for those  without PV (P=0.025). MHV thrombosis 
complicated pregnancies in 10 MHV patients (4.7%); 5 in the first trimester, which had been switched to 
some form of heparin. Hemorrhagic events were reported to occur in 23.1% of MHV, 5.1% with a THV 
(P<0.001), and 4.9% without PV (P<0.001). Only 58% of MHV had no serious adverse events compared 
with 79% with a THV (P<0.001) and 78% without a PV (P<0.001). OA use in the first trimester compared 
with heparin was associated with a higher rate of miscarriage (28.6% versus 9.2%; P<0.001) and late fetal 
death (7.1% versus 0.7%; P=0.016).10 
NOACS  
Regarding the use of new anticoagulants (NOACs) during pregnancy, there are no available data, as 
pregnancy was an exclusion criteria for the RCTs that these agents were tested in.11–14 However, the German 
Embryotox Pharmacovigilance Centre identified 63 exposed pregnancies associated with rivaroxaban use 
during childbearing age. All the women had discontinued rivaroxaban after the confirmation of pregnancy, 
mostly in the first trimester, while one patient continued therapy up until week 26. The registry recorded 
only one major fetal malformation in a mother who had had a previous fetus with cardiac malformation 
without exposure to rivaroxaban. Finally, a case of bleeding after a retrospective report of surgery for missed 
abortion was reported in this series. 15 
Aspirin 
A meta-analysis of 73 studies16 and a large (> 9,000 patients) RCT 17 both suggest that 60-150 mg/d of aspirin 
administered during the second and third trimesters of pregnancy is safe for the mother and fetus.  
Another meta-analysis of 8 studies, seven observational and one randomized, on the risk of congenital 
anomalies with aspirin exposure during the first trimester, reported no overall risk of congenital 
malformations associated with aspirin use18. However, aspirin use during the first trimester was associated 
with a 2-fold increased risk for gastroschisis. This risk estimate was calculated without taking into 
consideration variables including concomitant drug use and the selection of controls. Furthermore, diagnosis 
was not confirmed in all patients.18 Notably, another meta-analysis on preeclampsia suggests that aspirin is 
also beneficial in preventing preeclampsia when started before week 16.19 
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The effects of alternative antiplatelets such as clopidogrel, ticlopidine, dipiridamole, prasugrel and ticagrelor 
during pregnancy have never been systematically investigated (Tab. 2).  
Most available data on clopidogrel use during pregnancy comes from case reports on patients who had 
undergone coronary stent placement following a myocardial infarction (MI) either during or before 
pregnancy. Only one case report has been published on a successful gestation and delivery during clopidogrel 
use for secondary stroke prevention.20  
Regarding dipiridamole, the use of dipyridamole together with low doses of aspirin during pregnancies at 
high risk for preeclampsia has been reported to lower the incidence of preeclampsia, fetal loss, and fetal 
growth retardation, while abnormal bleeding was  not reported  for  mothers and neonates.21 
Only single case reports on women with previous MI using prasugrel or ticagrelor during pregnancy without 
negative results have been recently published 22,23. 
 
2. Methods of delivery 
2.1 Antithrombotic Discontinuation During Labor  
UFH can cause a persistent anticoagulant effect at the time of delivery, therein, its use prior to labor is not 
without risk.24 The bleeding risk associated with UFH can be assessed by APTT, however, during pregnancy 
its response to heparin is often attenuated because of increased levels of factor VIII and fibrinogen.25  
Bleeding complications have been rarely reported with LMWH.26 Friedrich et al. have reported anti-factor 
Xa activity levels to be sub-therapeutic in pregnant women receiving a twice daily regimen of therapeutic 
enoxaparin.27Regarding aspirin, it  can readily cross the placenta and, when given near term, can lead to 
higher concentrations in the neonate compared to the mother.28  
2.2 Choice of Delivery for Women with a History of Stroke 
Caesarean delivery has been reported to be an independent risk factor for stroke 29. We found few studies 
that had analyzed the modality of delivery in women with previous stroke.4,30 One of these studies 
interviewed 115 women as to their past method of child delivery: 88 (77%) vaginal, 19 (17%) caesarean 
sections and unknown for 8 (6%). Out of these 115 deliveries, 3 live births were reported in the first year 
after the index stroke, while 2 recurrent strokes during pregnancy; one due to essential thrombocytemia 
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and the second due to primary antiphospholipid syndrome4. Another study reported that among 29 
pregnant women with a history of stroke, 21 had full-term deliveries while 8 were preterm. Nine deliveries 
(31.1%) were caesareans, 1 (3.4%) forceps-assisted, and 19 (65.5%) non-induced vaginal deliveries. No 
recurrent strokes were reported 31.  Crovetto et al. reviewed the clinical reports of 24 pregnant women with 
previous stroke, reporting 11 caesarean sections and 13 vaginal deliveries. No recurrence of stroke was 
reported for these cases 30. The decision to perform caesarean section was based upon obstetrical 
indications and not on previous history of stroke.   
2.3  Resumption of Antithrombotics 
No RCTs or registry data are available on the resumption of antithrombotics following delivery. Yet, after 
minor general surgery or an invasive procedure, warfarin is generally resumed on the first evening after the 
procedure at the maintenance dose without a loading dose., While low molecular weight heparin, 
unfractionated heparin or NOACs are generally resumed 12–24 hours after minor general surgery32. 
 
3. Labor Induction  
Literature is lacking data regarding the benefit/risk of uterotonic drug induced deliveries in women with 
previous stroke. However, oxytocin does not significantly influence ATP-induced platelet aggregation, 
while prostaglandin F2α competitively inhibits ATP-induced platelet aggregation. 33  
 
4. Breastfeeding and Antiplatelets or Anticoagulants  
Warfarin 
Warfarin is not detectable in either maternal milk or infant plasma.34  
NOAC (New Anticoagulants)  
NOACs during breast-feeding have not been studied for infant safety.11–14 
Heparins  
The only published data on whether LMWHs are secreted in breast milk comes from a case series of 15 
women receiving LMWH after caesarean section,  where small amounts of heparin were detected in the 
breast milk of 11 patients.35  
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Aspirin 
It has been reported that 4–8% of the aspirin dose directly reached the nursing infant36 often causing  toxic 
accumulation due to the long elimination half-life of aspirin.37 Moreover, high doses of aspirin (2-4 g/day) 
have been associated with metabolic acidosis, theoretical risks of platelet dysfunction38, gastrointestinal 
bleeding and Reye’s syndrome in infants 39. Whereas, low-dose aspirin intake on the part of the mother 
appears to be safe for the platelet function of neonates during breastfeeding.40    
Clopidogrel 
The use of P2Y12 receptor blockers during pregnancy and their possible effects on breast milk have yet to be 
investigated. However, Clopidogrel has been reported to be successfully resumed after delivery.20 
Furthermore, prasugrel has been maintained for 15 months after delivery without complications,23 while 
Ticagrelor use has never been investigated during breastfeeding.  
 
5. Ovarian Stimulation  
Studies investigating the effects of ovarian stimulation in women with previous stroke have yet to be 
performed as women with previous stroke probably are unlikely to be offered ovarian stimulation. However, 
it has been hypothesized that elevated estradiol levels during ovarian stimulation with gonadotropins may 
cause a state of “hypercoagulability”, which could determine arterial or vein thrombosis 41. Strokes have 
been more frequently described in women with ovarian hyperstimulation syndrome (OHSS)42, but episodes 
have  also  been described in its absence.43 
 
6. Hormonal Contraceptive Therapy  
Regarding women with previous stroke on OCs, we were unable to find any data on safety as current 
guidelines recommend against the use of OCs in women with previous stroke.  
 
7. Hormonal Replacement therapy  
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Very limited data are available on the effects of ET or HRT as secondary stroke prevention. This type of 
data has only been derived from the HERS44, WEST45 and ESPRIT46 trials on women with major past 
cardiovascular events (either myocardial infarction or stroke), resulting both no statistically significant.  
However, most of these studies have investigated on the effects of conjugated equine estrogens, currently 
substituted by estradiol, for which data are extremely limited.  
Whereas, for herbal medicinal products, a Cochrane Database review examined all types of phytoestrogens 
including red clover extracts, dietary soy and soy extracts and concluded that there was no evidence to 
support a benefit for climacteric symptoms47. None of these alternative therapy studies examined their benefit 
on vascular prevention, but a number have reported that biochemical markers including arterial wall stiffness 
and apolipoprotein B are influenced by alternative treatment.48 
It has been reported that gabapentin which does not increase vascular risk, can reduce hot flushes49. 
Randomized placebo-controlled trials have shown that Selective serotonin reuptake inhibitors (SSRI) can 
reduce menopausal vasomotor symptoms (VMS) within 4 weeks of treatment50. However, SSRI exposure 
has been reported to be associated with  increased risks of intracerebral and intracranial hemorrhage51. On 
the other hand, a meta-analysis on the use of SSRIs in stroke survivors reported a non-significant excess of 
bleeding (RR 1.63; 95% CI 0.20 to 13.05).52 
Regular physical activity, no smoking habit, limited alcohol habit and BMI in the norm improve 
climacteric symptoms and reduce vascular risk. In fact, The American Heart Association’s “Life’s Simple 
7”53 defines  ideal cardiovascular life-style as : not smoking, regular physical activity, healthy diet, 
maintaining normal weight, and controls of  cholesterol,  blood pressure, and blood glucose levels. The 
achievement of  “Life’s Simple 7” goals has been associated with lower long-term risk of dying after 
stroke.53  
 
Discussion and considerations for future research  
This multidisciplinary expert consensus provides evidenced–based recommendations on the on the lifelong 
management of hormonal issues in women with previous stroke. Most of these recommendations are of 
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limited strength and are based upon observational data, and it is unlikely RCTs will provide data on these 
issues in the near future.  
This thorough review of current literature leads its Authors to recommend that women with past stroke be 
better followed up over their lifetimes to determine both the underlying role of pregnancy in stroke and its 
impact on the lifelong vascular risks for both mother and child through the application of this expert-based 
consensus document together with the participation in a future planned international registry for women with 
past stroke in childbearing age.  
The research community would benefit from pooling their data on pregnant women and stroke victims in 
order to realize a clearer picture on global trends concerning secondary prevention and    risk profiles both 
of which are responsible for death and disability rates worldwide. Data of this nature would provide the 
much-needed insight into the treatment safety and efficacy regarding antiplatelet selection and dosage and 
could aid in better define predictive factors. 
An additional priority of future  research  should  be to investigate on  the   role of  ovarian stimulation on 
the vascular  state,  as  this  therapy  is widely  sought  out by women  due  to  falling fertility  rates  worldwide.  
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Table 1. Recommendations  
QUESTIONS RECOMMENDATIONS GRADE LEVEL 
Point 1 
a) Future 
pregnancies 
 
 
b) Secondary 
prevention 
 
For women with a history of stroke, future pregnancies are not 
contraindicated based on available data. 
 
 
Pregnant women with defined low risk condition may be considered for 
treatment with UFH or LMWH throughout the first trimester, followed by 
low-dose aspirin for the remainder of the pregnancy 
 
 
In pregnant women with defined low risk conditions no recommendations 
on other types of antiplatelets  other than aspirin can be given 
 
 
In pregnant women with defined high risk conditions, Vitamin K 
antagonists should be avoided between the 6th and 12th weeks of gestation 
and close to term, in order to avoid the delivery of an anticoagulated fetus. 
LMWH or UFH should be used either during these above periods alone and 
alternated with Vitamin K antagonists that have the same target INR based 
upon previous prescription, or during the entire pregnancy. 
 
 
High risk condition women on NOAC treatment should be prescribed 
LMWH or UFH between the 6th and 12th week of gestation, while warfarin 
can be administered in the other periods. The Vitamin K antagonist target 
INR needs to be based on the underlying pathology. Alternatively, UFH or 
LMWH may be prescribed throughout pregnancy 
 
2 
 
 
2  
 
 
2 
 
 
2 
 
 
 
 
2 
 
B 
 
 
B 
 
 
C  
 
 
B 
 
 
 
 
C  
Point 2 
Methods of delivery 
 
Natural birth may be preferred to caesarean section. Caesarean section 
should be performed based upon obstetrical indications and not on previous 
history of stroke 
2  C 
Point 3 
Labor induction 
 
When labor is pharmacologically induced, aspirin therapy may be 
continued 
 
Therapeutic doses of UFH/LMWH should be discontinued 24 h prior to 
inducing labor and restarted within 24 hours if no contra-indications exist 
 
 
2 
 
2  
 
2  
 
C 
 
C 
 
C 
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Tab 2. Associated Teratogenic risks from antithrombotic therapies. 
Vitamin K antagonists may be restarted after 24 hours after delivery 
without a loading dose 
Point 4 
a) Breastfeeding 
during antiplatelet 
treatment 
 
 
b) Breastfeeding 
during 
anticoagulant 
treatment 
 
 
Low-dose aspirin use during breastfeeding may be recommended 
 
No recommendations on antiplatelets besides aspirin during breastfeeding 
can be given  
 
Vitamin K antagonist use during breastfeeding may be recommended.  
 
UFH/LMH during breastfeeding during breastfeeding may be 
recommended. 
 
NOACs should be avoided during breastfeeding and when necessary 
substituted with LMWH/ UFH or Vitamin K antagonists 
 
2 
 
2  
 
2 
 
2   
 
2 
 
C 
 
C 
 
C 
 
C 
 
C 
Point 5 
Ovarian stimulation 
 
In women with previous stroke no recommendation on ovarian stimulation 
could be given  
2  C 
Point 6  
Hormonal 
contraceptive therapy 
 
OC should not be recommended to women with previous stroke  
 
 
1 
 
B 
Point 7 
a) Hormonal 
replacement 
therapy and 
alternative 
strategies  
 
 
HRT should not be recommended to women with previous stroke  
 
In women with previous stroke Gabapentin may be recommended for hot 
flashes.  
 
In women with previous stroke no recommendation on the use of SSRI for 
hot flashes could be given 
 
Smoking habit, physical inactivity and a BMI above normal should be 
discouraged in menopausal women with previous stroke 
 
1 
 
2  
 
2 
 
2  
 
A 
 
C 
 
C 
 
B 
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Antithrombotic drugs Placental transfer First trimester Second and third trimester 
Low-dose Aspirin (60 to 150 
mg/d) 
Yes Contraindicated (risk of 
gastroschisis) 
Not contraindicated 
Other antiplatelets No data No data No data 
Warfarin Yes  Contraindicated (teratogenic) Not contraindicated 
Regular check of INR 
UFH No Not contraindicated  
Risk of HIT 
Not contraindicated 
Risk of HIT 
Regular check of apTT 
LMWH No Not contraindicated  Not contraindicated  
NOAC Dabigatran: yes  
Rivaroxaban: yes 
Apixaban: no data 
Edoxaban: no data 
No data  No data  
 
 
 
Fig.1 Flow chart of the research strategy 
 
 
 
